Jun 03, 2025
Beam Therapeutics Secures FDA Orphan Drug Designation for BEAM-302 in AATD Beam Therapeutics Inc. announced that the FDA has granted Orphan Drug Designation to its investigational therapy, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (AATD). BEAM-302 is a liver-targeting lipid nanoparticle (LNP)...
Read More...
Jan 06, 2025
Eli Lilly’s blockbuster weight loss GLP-1 drug ZEPBOUND has received FDA approval to treat obstructive sleep apnea in adults with obesity, alongside diet and exercise. This marks the first FDA-approved medication for obstructive sleep apnea. The approval adds a second indication for ZEPBOUND, following its...
Read More...
May 30, 2022
Obstructive Sleep Apnea (OSA) is a common, chronic, sleep-related breathing disorder characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep, leading to either complete or partial obstruction of the airway, resulting in apneas, hypopneas, or both. Obstructive Sleep Apnea causes day...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper